enow.com Web Search

Search results

  1. Results from the WOW.Com Content Network
  2. Cabotegravir/rilpivirine - Wikipedia

    en.wikipedia.org/wiki/Cabotegravir/rilpivirine

    The most common adverse reactions include injection site reactions, fever or feeling hot (pyrexia), fatigue, headache, musculoskeletal pain, nausea, sleep disorders, dizziness and rash. [ 3 ] [ 4 ] [ 8 ]

  3. Cabotegravir - Wikipedia

    en.wikipedia.org/wiki/Cabotegravir

    Cabotegravir, sold under the brand name Vocabria among others, is a antiretroviral medication used for the treatment of HIV/AIDS. It is available in the form of tablets and as an intramuscular injection, as well as in an injectable combination with rilpivirine under the brand name Cabenuva. [8] [14]

  4. GSK's injectable HIV drug shows promise over daily pills - AOL

    www.aol.com/news/gsks-injectable-hiv-drug-shows...

    Strong sales of medicines for HIV, the virus that causes AIDS, were one of the drivers behind the company's performance last year, generating 6.44 billion pounds ($8.13 billion) in annual sales.

  5. GSK says within weeks of resubmitting HIV injection Cabenuva

    www.aol.com/news/gsk-says-within-weeks...

    GlaxoSmithKline's HIV business ViiV is within weeks of resubmitting its request for approval of its long-acting injection Cabenuva to U.S. drug regulators, ViiV's head of research said on Thursday.

  6. List of antiretroviral fixed-dose combinations - Wikipedia

    en.wikipedia.org/wiki/List_of_antiretroviral...

    Antiretroviral drugs are used to manage HIV/AIDS. Multiple antiretroviral drugs are often combined into a single pill in order to reduce pill burden. Some of these combinations are complete single-tablet regimens; the others must be combined with additional pills to make a treatment regimen.

  7. GSK lifts growth target for HIV business on demand for long ...

    www.aol.com/news/gsk-lifts-growth-ambitions-hiv...

    The HIV business, the focus of a GSK's capital markets day on Thursday, is now targeting annual rates of sales growth of between 6% and 8%, to reach between 6 billion pounds ($7.31 billion) and 7 ...

  8. Experts say a twice-yearly injection that offers 100% ...

    lite.aol.com/news/health/story/0001/20240724/a94...

    There were no infections in the young women and girls that got the shots in a study of about 5,000 in South Africa and Uganda, researchers reported. In a group given daily prevention pills, roughly 2% ended up catching HIV from infected sex partners. “To see this level of protection is stunning,” said Salim Abdool Karim of the injections.

  9. Rilpivirine - Wikipedia

    en.wikipedia.org/wiki/Rilpivirine

    Rilpivirine, sold under the brand names Edurant and Rekambys, is a medication, developed by Tibotec, used for the treatment of HIV/AIDS. [5] [6] It is a second-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) with higher potency, longer half-life and reduced side-effect profile compared with older NNRTIs such as efavirenz.